Evidence map›Paper›PMID 31316003›Full record

ArticleScience translational medicine2019

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Danilo Perrotti, Anupriya Agarwal, Claire M Lucas, Goutham Narla, Paolo Neviani, Maria D Odero, Peter P Ruvolo, Nicole M Verrills

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Targeting Phosphatases and Kinases: How to Checkmate Cancer.Frontiers in cell and developmental biology · 2021
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Danilo PerrottiUniversity of Maryland School of Medicine, Baltimore, MD 21201, USA. dperrotti@som.umaryland.edu.ORCID 0000-0003-0726-8766
Anupriya AgarwalKnight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
Claire M LucasUniversity of Chester Medical School, Chester CH2 1BR, UK.
Goutham NarlaDepartment of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-4098-4203
Paolo NevianiKeck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.
Maria D OderoUniversity of Navarra, Pamplona 31009, Spain.ORCID 0000-0002-8858-2054
Peter P RuvoloDepartment of Leukemia, MD Anderson Cancer Center, Houston, 77054 TX, USA.
Nicole M VerrillsSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0002-7894-0137

Funding

Structural and molecular determinants of protein phosphatase 2A in Alzheimer's DiseaseR01CA240993 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NARLA, GOUTHAM, TAYLOR, DEREK JAMES · 2019 to 2023
$3.4M
Role of Protein Phosphatase 2A in Aortic AneurysmR01HL144741 · NHLBI · EMORY UNIVERSITY · PI LIN, ZHIYONG, NARLA, GOUTHAM · 2019 to 2022
$2.2M
Small Molecule Activators of PP2A (SMAPs) for Prostate Cancer TherapyR01CA181654 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NARLA, GOUTHAM · 2015 to 2019
$1.9M
Studying drug resistance in AML and PDAC using a novel heterotypic 3D organoid modelR01CA229875 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI AGARWAL, ANUPRIYA · 2019 to 2023
$1.6M
NCI NIH HHS R01 CA181654NCI NIH HHS R01 CA229875NCI NIH HHS R01 CA240993NHLBI NIH HHS R01 HL144741
6 · The paper itself

Abstract

LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveApoptosisDrug Resistance, NeoplasmFusion Proteins, bcr-ablHumansNeoplastic Stem CellsProtein Kinase InhibitorsFusion Proteins, bcr-ablProtein Kinase Inhibitors

Identifiers

PMID31316003
PMCPMC7402218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.